Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats

Endocrine

Volumn 49, Issue 1, 2015, Pages 106-118

  Yang, Jing ^a   Ao, Na ^a   Du, Jian ^a   Wang, Xiaochen ^a   He, Yini ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemerin; ER stress; GLP 1 analog; Insulin resistance; Liraglutide; Liver

Indexed keywords

ANTIDIABETIC AGENT; CHEMERIN PROTEIN, RAT; CHEMOKINE; LIRAGLUTIDE; SIGNAL PEPTIDE;

ANIMAL; BLOOD; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CHEMOKINES; DIET, HIGH-FAT; ENDOPLASMIC RETICULUM STRESS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIRAGLUTIDE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84939933576     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0480-y     Document Type: Article

References (42)

1. J.F. Gautier, S.P. Choukem, J. Girard, Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metabol. 34(Suppl 2), S65–S72 (2008). doi:10.1016/S1262-3636(08)73397-4
2. C.F. Deacon, Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53(9), 2181–2189 (2004)
3. M. Parks, C. Rosebraugh, Weighing risks and benefits of liraglutide: the FDA’s review of a new antidiabetic therapy. New Engl. J. Med. 362(9), 774–777 (2010). doi:10.1056/NEJMp1001578
4. K.R. Peters, Liraglutide for the treatment of type 2 diabetes: a clinical update. Am. J. Ther. 20(2), 178–188 (2013). doi:10.1097/MJT.0b013e3182204c16
5. M. Horowitz, A. Flint, K.L. Jones, C. Hindsberger, M.F. Rasmussen, C. Kapitza, S. Doran, T. Jax, M. Zdravkovic, I.M. Chapman, Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract. 97(2), 258–266 (2012). doi:10.1016/j.diabres.2012.02.016
6. Knudsen, L.B.: Liraglutide: the therapeutic promise from animal models. Int. J. Clin Pract. 64(167), 4–11 (2010). doi:10.1111/j.1742-1241.2010.02499.x
7. T. Schwasinger-Schmidt, D.C. Robbins, S.J. Williams, L. Novikova, L. Stehno-Bittel, Long-term liraglutide treatment is associated with increased insulin content and secretion in beta-cells, and a loss of alpha-cells in ZDF rats. Pharmacol. Res. 76, 58–66 (2013). doi:10.1016/j.phrs.2013.07.005
8. C.W. Spellman, Incorporating glucagon-like peptide-1 receptor agonists into clinical practice. J. Am. Osteopath. Assoc. 112(1 suppl 1), S7–S15 (2012)
9. S. Chen, W.B. Melchior Jr, L. Guo, Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity. J. Environ. Sci. Health C 32(1), 83–104 (2014). doi:10.1080/10590501.2014.881648
10. H. Malhi, R.J. Kaufman, Endoplasmic reticulum stress in liver disease. J. Hepatol. 54(4), 795–809 (2011). doi:10.1016/j.jhep.2010.11.005
11. Y. Ji, Z. Zhao, T. Cai, P. Yang, M. Cheng, Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-alpha pathway. Mol. Med. Rep. 9(4), 1254–1258 (2014). doi:10.3892/mmr.2014.1956
12. J. Liu, Y. Liu, L. Chen, Y. Wang, J. Li, Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J. Diabetes Res. 2013, 630537 (2013). doi:10.1155/2013/630537
13. L. Zhao, H. Guo, H. Chen, R.B. Petersen, L. Zheng, A. Peng, K. Huang, Effect of Liraglutide on endoplasmic reticulum stress in diabetes. Biochem. Biophys. Res. Commun. 441(1), 133–138 (2013). doi:10.1016/j.bbrc.2013.10.026
14. D.Y. Jung, U. Chalasani, N. Pan, R.H. Friedline, D.A. Prosdocimo, M. Nam, Y. Azuma, R. Maganti, K. Yu, A. Velagapudi, B. O’Sullivan-Murphy, J.L. Sartoretto, M.K. Jain, M.P. Cooper, F. Urano, J.K. Kim, S. Gray, KLF15 is a molecular link between endoplasmic reticulum stress and insulin resistance. PLoS One 8(10), e77851 (2013). doi:10.1371/journal.pone.0077851
15. E. Panzhinskiy, J. Ren, S. Nair, Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B axis. PLoS One 8(10), e77228 (2013). doi:10.1371/journal.pone.0077228
16. Y.L. Chu, Y.D. Gong, Z.H. Su, H.N. Yu, Q. Cui, H.Y. Jiang, H.M. Qu, Relationship between tyrosine phosphorylation and protein expression of insulin receptor and insulin resistance in gestational diabetes mellitus. J. Huazhong Univ. Sci. Technol. Med. Sci. 34(3), 393–397 (2014). doi:10.1007/s11596-014-1289-x
17. Z.C. Wang, J.F. Wang, Y.B. Li, C.X. Guo, Y. Liu, F. Fang, S.L. Gong, Involvement of endoplasmic reticulum stress in apoptosis of testicular cells induced by low-dose radiation. J. Huazhong Univ. Sci. Technol. Med. Sci. 33(4), 551–558 (2013). doi:10.1007/s11596-013-1157-0
18. M. Becker, K. Rabe, C. Lebherz, J. Zugwurst, B. Goke, K.G. Parhofer, M. Lehrke, U.C. Broedl, Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 59(11), 2898–2903 (2010). doi:10.2337/db10-0362
19. K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, D. Segal, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148(10), 4687–4694 (2007). doi:10.1210/en.2007-0175
20. K. Bozaoglu, D. Segal, K.A. Shields, N. Cummings, J.E. Curran, A.G. Comuzzie, M.C. Mahaney, D.L. Rainwater, J.L. VandeBerg, J.W. MacCluer, G. Collier, J. Blangero, K. Walder, J.B. Jowett, Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J. Clin. Endocrinol. Metabol. 94(8), 3085–3088 (2009). doi:10.1210/jc.2008-1833
21. M.C. Ernst, I.D. Haidl, L.A. Zuniga, H.J. Dranse, J.L. Rourke, B.A. Zabel, E.C. Butcher, C.J. Sinal, Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 153(2), 672–682 (2012). doi:10.1210/en.2011-1490
22. M.C. Ernst, M. Issa, K.B. Goralski, C.J. Sinal, Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151(5), 1998–2007 (2010). doi:10.1210/en.2009-1098
23. S.S. Fatima, K. Bozaoglu, R. Rehman, F. Alam, A.S. Memon, Elevated chemerin levels in Pakistani men: an interrelation with metabolic syndrome phenotypes. PLoS One 8(2), e57113 (2013). doi:10.1371/journal.pone.0057113
24. J.L. Rourke, H.J. Dranse, C.J. Sinal, Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes. Rev. 14(3), 245–262 (2013). doi:10.1111/obr.12009
25. M. Takahashi, Y. Takahashi, K. Takahashi, F.N. Zolotaryov, K.S. Hong, R. Kitazawa, K. Iida, Y. Okimura, H. Kaji, S. Kitazawa, M. Kasuga, K. Chihara, Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 582(5), 573–578 (2008). doi:10.1016/j.febslet.2008.01.023
26. H. Malhi, G.J. Gores, Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28(4), 360–369 (2008). doi:10.1055/s-0028-1091980
27. C. Owman, S.J. Lolait, S. Santen, B. Olde, Molecular cloning and tissue distribution of cDNA encoding a novel chemoattractant-like receptor. Biochem. Biophys. Res. Commun. 241(2), 390–394 (1997). doi:10.1006/bbrc.1997.7822
28. L. Pei, J. Yang, J. Du, H. Liu, N. Ao, Y. Zhang, Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats. Diabetes Res. Clin. Pract. 97(2), 267–275 (2012). doi:10.1016/j.diabres.2012.02.023
29. J. Lamontagne, E. Jalbert-Arsenault, E. Pepin, M.L. Peyot, N.B. Ruderman, C.J. Nolan, E. Joly, S.R. Madiraju, V. Poitout, M. Prentki, Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes 62(6), 2122–2129 (2013). doi:10.2337/db12-0428
30. Z. Luo, H. Liu, X. Sun, R. Guo, R. Cui, X. Ma, M. Yan, RNA interference against discoidin domain receptor 2 ameliorates alcoholic liver disease in rats. PLoS One 8(2), e55860 (2013). doi:10.1371/journal.pone.0055860
31. G.S. Hotamisligil, Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140(6), 900–917 (2010). doi:10.1016/j.cell.2010.02.034
32. H. Li, X. Yu, Emerging role of JNK in insulin resistance. Curr. Diabetes Rev. 9(5), 422–428 (2013)
33. A. Bettaieb, M.A. Vazquez Prieto, C. Rodriguez Lanzi, R.M. Miatello, F.G. Haj, C.G. Fraga, P.I. Oteiza, (−)-Epicatechin mitigates high-fructose-associated insulin resistance by modulating redox signaling and endoplasmic reticulum stress. Free Radic. Biol. Med. 72, 247–256 (2014). doi:10.1016/j.freeradbiomed.2014.04.011
34. Y. Han, H.W. Jung, H.S. Bae, Y.K. Park, Wen-pi-tang-Hab-Wu-ling-san, a polyherbal medicine, attenuates ER stress in 3T3-L1 preadipocytes by promoting the insulin signaling pathway. Evid. Complement. Altern. Med. 2013, 825814 (2013). doi:10.1155/2013/825814
35. Y.Y. Wang, S.Y. Lin, Y.H. Chuang, W.H. Sheu, K.C. Tung, C.J. Chen, Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. Endocrinology 155(4), 1235–1246 (2014). doi:10.1210/en.2013-1593
36. L. Xu, G.A. Spinas, M. Niessen, ER stress in adipocytes inhibits insulin signaling, represses lipolysis, and alters the secretion of adipokines without inhibiting glucose transport. Hormone Metabol. Res. 42(9), 643–651 (2010). doi:10.1055/s-0030-1255034
37. P. Hu, Z. Han, A.D. Couvillon, R.J. Kaufman, J.H. Exton, Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol. Cell. Biol. 26(8), 3071–3084 (2006). doi:10.1128/MCB.26.8.3071-3084.2006
38. S. Kralisch, S. Weise, G. Sommer, J. Lipfert, U. Lossner, M. Bluher, M. Stumvoll, M. Fasshauer, Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul. Pept. 154(1–3), 102–106 (2009). doi:10.1016/j.regpep.2009.02.010
39. D. Wang, G.Y. Yuan, X.Z. Wang, J. Jia, L.L. Di, L. Yang, X. Chen, F.F. Qian, J.J. Chen, Plasma chemerin level in metabolic syndrome. Genet. Mol. Res. 12(4), 5986–5991 (2013). doi:10.4238/2013.November.26.8
40. A.A. Alfadda, R.M. Sallam, M.A. Chishti, A.S. Moustafa, S. Fatma, W.S. Alomaim, M.Y. Al-Naami, A.F. Bassas, G.P. Chrousos, H. Jo, Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol. Cells 33(6), 591–596 (2012). doi:10.1007/s10059-012-0012-7
41. R. Chakaroun, M. Raschpichler, N. Kloting, A. Oberbach, G. Flehmig, M. Kern, M.R. Schon, E. Shang, T. Lohmann, M. Dressler, M. Fasshauer, M. Stumvoll, M. Bluher, Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metab. Clin. Exp. 61(5), 706–714 (2012). doi:10.1016/j.metabol.2011.10.008
42. P. Fietta, G. Delsante, Focus on adipokines. Theor. Biol. Forum 106(1–2), 103–129 (2013)